- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:44 | XFRA F3Y: AUSSETZUNG/SUSPENSION | 171 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMICROBA LIFE SCIENCES... ► Artikel lesen | |
| MICROBA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 01:00 | MICROBA LIFE SCIENCES LIMITED: Trading Halt | - | ASX | ||
| 00:49 | MICROBA LIFE SCIENCES LIMITED: Pause in Trading | - | ASX | ||
| 30.04. | MICROBA LIFE SCIENCES LIMITED: Notification of cessation of securities - MAP | - | ASX | ||
| 30.04. | Microba Q3 FY26 slides: 99% revenue growth amid cash constraints | 3 | Investing.com | ||
| 30.04. | MICROBA LIFE SCIENCES LIMITED: Q3 FY26 Quarterly Activities Report & Appendix 4C | - | ASX | ||
| 28.04. | MICROBA LIFE SCIENCES LIMITED: Details of Q3 FY26 Quarterly Report, Appendix 4C & Webinar | - | ASX | ||
| 25.02. | MICROBA LIFE SCIENCES LIMITED: Appendix 4D & FY26 Interim Report | - | ASX | ||
| 29.01. | Microba Q2 FY26 slides: 90% test volume growth, UK expansion accelerates | 1 | Investing.com | ||
| 28.01. | MICROBA LIFE SCIENCES LIMITED: Q2 FY26 Quarterly Investor Presentation & Webinar | - | ASX | ||
| 28.01. | MICROBA LIFE SCIENCES LIMITED: Q2 FY26 Quarterly Activities Report & Appendix 4C | - | ASX | ||
| 21.01. | MICROBA LIFE SCIENCES LIMITED: Details of Q2 FY26 Quarterly Report, Appendix 4C & Webinar | - | ASX | ||
| 01.07.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.07.2025 | 1.118 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.07.2025
Aktien
1 LU2559000059 Moolec Science S.A.
2... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 258,08 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,480 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | 0,00 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | -0,06 % | Relay Therapeutics Shares Jump 18% | ||
| COGENT BIOSCIENCES | 32,760 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | +0,13 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | +0,02 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,690 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DISC MEDICINE | 68,00 | 0,00 % | Disc Medicine launches expanded access program for bitopertin | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,615 | +0,14 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| MINERALYS THERAPEUTICS | 28,850 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection ... | - Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease - - In participants... ► Artikel lesen | |
| CG ONCOLOGY | 55,47 | -0,11 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| IMMUNOVANT | 30,920 | 0,00 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data |
MICROBA LIFE SCIENCES LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,034 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MICROBA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.